Skip to content

Exelixis EXEL Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$21M-320%
Pfizer logo
PfizerPFE
Incyte logo
IncyteINCY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's other noncash income (expense)?
Exelixis (EXEL) reported other noncash income (expense) of $2.02M in Q1 2026.
How has Exelixis's other noncash income (expense) changed year-over-year?
Exelixis's other noncash income (expense) decreased by 57.8% year-over-year, from $4.79M to $2.02M.
What is the long-term trend for Exelixis's other noncash income (expense)?
Over 2 years (2022 to 2024), Exelixis's other noncash income (expense) has grown at a 409.5% compound annual growth rate (CAGR), from $525K to $13.63M.